Your email has been successfully added to our mailing list.

×
0.00100905727771395 0.00146702385508349 -0.000765403750478406 0.000925500701620191 0.00216864395968876 0.0140324020921035 0.0116092613853808 0.0102053833397117
Stock impact report

Germany's BioNTech Sued By Rival Over Covid Jab Formula [Barron's]

BioNTech SE - American Depositary Shares (BNTX) 
Company Research Source: Barrons
CureVac intends to "assert its intellectual property rights, accumulated over more than two decades of pioneering work in mRNA technology, which contributed to Covid-19 vaccine development", it said in a statement. The lawsuit against Mainz-based BioNTech and two of its subsidiaries will seek "fair compensation" for infringement of intellectual property rights, the company said. The Comirnaty jab developed by BioNTech with US pharma giant Pfizer was the first Covid-19 shot to be approved in the West and has become one of the most widely used around the world. Show less Read more
Impact Snapshot
Event Time:
BNTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for BNTX alerts
Opt-in for
BNTX alerts

from News Quantified
Opt-in for
BNTX alerts

from News Quantified